Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors

BACKGROUNDS/AIMS: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials. In this second stage of our ongoing study, we intend to analyze the...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorat, Ashok, Jeng, Long-Bin, Yang, Horng-Ren, Yeh, Chun-Chieh, Hsu, Shih-Chao, Chen, Te-Hung, Poon, Kin-Shing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Hepato-Biliary-Pancreatic Surgery 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740/
https://www.ncbi.nlm.nih.gov/pubmed/29264583
http://dx.doi.org/10.14701/ahbps.2017.21.4.205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736740/
https://www.ncbi.nlm.nih.gov/pubmed/29264583
http://dx.doi.org/10.14701/ahbps.2017.21.4.205

Ejemplares similares